Experimental gene therapy targets rare immune disorder in first human test

NCT ID NCT06959771

First seen Jan 04, 2026 · Last updated May 08, 2026 · Updated 17 times

Summary

This study tests a one-time gene therapy for a rare immune disease called CD40L-HyperIgM syndrome, which causes severe infections and autoimmune problems. One male participant will receive his own stem cells and T cells that have been corrected in the lab using a precise editing technique. Before the infusion, he will get chemotherapy to prepare his body. The goal is to see if the treatment is safe and can restore immune function, with follow-up over 15 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD40L-HYPERIGM SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.